Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML

NCT02658487 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT02658487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02658487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2016
Completion date
September 30, 2024
Enrollment
42 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), acute myeloid leukemia arising from previous myelodysplastic syndrome, acute myeloid leukemia with multilineage dysplasia, myeloid sarcoma, secondary acute myeloid leukemia, therapy-related acute myeloid leukemia, therapy-related myelodysplastic syndrome